Physician profile
Scott A Edison
NPI 1124032032
$13,845.49
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,348 · 2020: $1,168 · 2021: $1,936 · 2022: $2,026 · 2023: $2,799 · 2024: $3,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,274 · Education: $92.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,273.98 |
| Education | $92.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,130.45 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,006.70 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,597.36 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,487.54 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $1,140.25 | 2019-2024 | |
| Qol Medical, LLC | $577.58 | 2019-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $459.36 | 2019-2023 | Sutab |
| Celgene Corporation | $440.63 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $412.53 | 2019-2024 | Rebyota, Clenpiq, Cimzia |
| Merck Sharp & Dohme LLC | $330.50 | 2019-2024 | Dificid, Bridion |
| Ucb, INC. | $301.65 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $296.04 | 2019-2024 | Ocaliva |
| Lilly USA, LLC | $185.05 | 2023-2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $179.51 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $178.23 | 2019-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Edison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.